Email Alert | RSS    帮助

中国防痨杂志 ›› 2020, Vol. 42 ›› Issue (9): 910-915.doi: 10.3969/j.issn.1000-6621.2020.09.005

• 论著 • 上一篇    下一篇

《WS 288—2017 肺结核诊断》标准实施后肺结核诊断质量评估分析

周林(), 刘二勇, 孟庆琳, 陈明亭(), 周新华, 高微微, 林明贵, 谢汝明   

  1. 102206 北京,中国疾病预防控制中心结核病预防控制中心(周林、刘二勇、孟庆琳、陈明亭);首都医科大学附属北京胸科医院放射科(周新华),结核内科(高微微);清华大学附属北京清华长庚医院感染科(林明贵);首都医科大学附属北京地坛医院放射科(谢汝明)
  • 收稿日期:2020-06-10 出版日期:2020-09-10 发布日期:2020-09-18
  • 通信作者: 周林,陈明亭 E-mail:zhoulin@chinacdc.cn;chenmt@chinacdc.cn
  • 基金资助:
    “十三五”艾滋病和病毒性肝炎等重大传染病防治国家科技重大专项(2018ZX10722-301-004)

Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards

ZHOU Lin(), LIU Er-yong, MENG Qing-lin, CHEN Ming-ting(), ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming   

  1. National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206,China
  • Received:2020-06-10 Online:2020-09-10 Published:2020-09-18
  • Contact: ZHOU Lin,CHEN Ming-ting E-mail:zhoulin@chinacdc.cn;chenmt@chinacdc.cn

摘要:

目的 了解《WS 288—2017 肺结核诊断》标准(以下简称“新标准”)实施后肺结核诊断情况,提高登记治疗的肺结核患者病原学阳性率,以及对病原学阴性肺结核患者的诊断质量。方法 以自愿接受评估为原则,青海、甘肃、新疆、贵州、湖北、广西、山东、辽宁8个省(自治区)接受现场评估,每个省1家地市级、3家县级结核病定点医疗机构。评估内容:查阅“新标准”实施前1年(2017年)、实施后1年(2018年)当地肺结核登记资料,以及结核病影像学诊断、结核病实验室相关检测情况;查阅病原学阴性肺结核病案,每个现场、每个年度从发现第一例患者开始采用整群抽样方法各查阅50例;查阅实验室登记本、留存痰涂片,累计查阅病原学阴性肺结核患者病案3532例,实验室留存痰涂片3260份。计数资料的比较采用χ2检验,以P<0.05为差异有统计学意义。结果 “新标准”实施后各评估现场强化了病原学检测力度,分枝杆菌分子生物学检测率由实施前的18.2%(6/33)提高到60.0%(15/25),差异有统计学意义(χ2=9.035,P=0.003);分枝杆菌分离培养率由93.9%(31/33)提高到96.0%(24/25),差异无统计学意义(χ2=0.061,P=0.804)。实验室检测质量评估发现,2017年度痰标本不合格率为40.1%(384/957),2018年度为40.0%(922/2303),差异无统计学意义(χ2=0.000,P=0.993)。“新标准”实施后,评估地区登记肺结核患者病原学阳性率从21.6%(4806/22258)提高到24.7%(4026/16300),差异有统计学意义(χ2=51.200,P=0.000);结核抗原抗体检测率从36.5%(871/2389)提高到37.3%(426/1143),差异无统计学意义(χ2=0.186,P=0.667);结核抗原抗体检测阳性率从25.7%(224/871)提高到41.3%(176/426),差异有统计学意义(χ2=31.900,P=0.000);结核菌素试验检测率从23.0%(549/2389)提高到47.2%(539/1143),阳性率由57.9%(318/549)提高到73.3%(395/539),差异均有统计学意义(χ2值分别为210.900、27.730,P值均=0.000);γ干扰素释放试验检测率由2.3%(54/2389)提高到17.2%(197/1143),差异有统计学意义(χ2=260.400,P=0.000)。符合肺结核临床诊断要素的患者从23.8%(569/2389)提高到48.1%(550/1143),差异有统计学意义(χ2=209.800,P=0.000)。结论 “新标准”贯彻实施后提高了登记肺结核患者的病原学阳性率,改进了病原学阴性肺结核诊断质量。

关键词: 结核,肺, 诊断, 执行功能, 结果评价(卫生保健), 对比研究, 数据说明,统计

Abstract:

Objective To understand the status of pulmonary tuberculosis (TB) diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standard (hereinafter referred to as “new standard”), and the effect in improving the proportion of pathogenic positive in the patients registered for treatment and the quality of diagnosis in the patients with negative pathogen.Methods In accordance with the principle of voluntary assessment, eight provinces (Qinghai, Gansu, Xinjiang, Guizhou, Hubei, Guangxi, Shandong and Liaoning) were assessed, with one municipal specific hospital and three county-level institutions in each province. Assessment contents: the local tuberculosis registration data, tuberculosis imaging diagnosis and tuberculosis laboratory related tests before (2017) and after (2018) the implementation of the new standard were reviewed; the pathogenic negative pulmonary tuberculosis medical records, 50 cases in each site and each year were checked, as well as the laboratory register and retained sputum smear slides. A total of 3532 medical records of pathogenic negative pulmonary tuberculosis patients and 3260 sputum smears retained in the laboratory were checked. Chi-square test was used to compare the count data, with P<0.05 as the difference statistically significant.Results After the implementation of the new standard, the detection ability of mycobacterium molecular biology increased from 18.2% (6/33) to 60.0% (15/25), the difference was statistically significant (χ2=9.035, P=0.003). The isolation and culture of mycobacterium increased from 93.9% (31/33) to 96.0% (24/25), with no significant difference (χ2=0.061, P=0.804). Through laboratory test quality assessment, we found that the quality of sputum specimen was not improved, 40.1% (384/957) of unqualified sputum samples in 2017 and 40.0% (922/2303) in 2018, and the difference was not statistically significant (χ2=0.000, P=0.993). The pathogenic positive rate of registered tuberculosis patients increased from 21.6% (4806/22258) to 24.7% (4026/16300), and the difference was statistically significant (χ2=51.200, P=0.000). The detection rate of tuberculosis antigen and antibody increased from 36.5% (871/2389) to 37.3% (426/1143), without statistically significant difference (χ2=0.186, P=0.667). The positive rate of tuberculosis antigen and antibody increased from 25.7% (224/871) to 41.3% (176/426), the difference was statistically significant (χ2=31.900, P=0.000). The detection rate of tuberculin test increased from 23.0% (549/2389) to 47.2% (539/1143), and the positive rate increased from 57.9% (318/549) to 73.3% (395/539), the difference was statistically significant (χ2=210.900, P=0.000; χ2=27.730, P=0.000). The detection rate of IFN-γ release test increased from 2.3% (54/2389) to 17.2% (197/1143), the difference was statistically significant (χ2=260.400, P=0.000). Patients met the clinical TB diagnosis standard increased from 23.8% (569/2389) to 48.1% (550/1143), the difference was statistically significant (χ2=209.800, P=0.000).Conclusion The implementation of the new standard has increased the pathogenic positive rate of registered pulmonary tuberculosis patients and improved the diagnostic quality of pathogenic negative pulmonary tuberculosis.

Key words: Tuberculosis,pulmonary, Diagnosis, Implementation, Outcome assessment (health care), Comparative study, Data interpretation,statistical